Why the NHS Modern Service Framework Matters for Heart Valve Disease
The NHS Modern Service Framework (MSF) is designed to shape how services are organised and delivered for the future. It brings together clinical evidence, system planning and patient experience to improve outcomes and reduce variation in care. For those of us working in heart valve disease, it represents an important moment, and a significant opportunity.
I was honoured to be asked to contribute to the data-gathering process that informed the development of the Framework. Ensuring that real patient experiences were reflected in those conversations was vital. Patients and carers consistently tell us about delays, confusion, missed symptoms and the anxiety of navigating a fragmented system. These experiences must sit alongside the clinical evidence and operational data if the Framework is to deliver meaningful change.
Too many people in the UK still live with symptoms of heart valve disease for years before diagnosis. Breathlessness is attributed to ageing. Fatigue is blamed on lifestyle. Dizziness or reduced exercise tolerance is written off as “just getting older.” In many cases, symptoms are documented repeatedly in primary care before a murmur is recognised or an echocardiogram is requested. By the time the condition is formally diagnosed, patients may already be significantly unwell.
We must move away from thinking this is inevitable, heart valve disease is common and serious, but it is detectable and treatable. When identified early and managed through timely elective intervention, outcomes are excellent. The challenge is not a lack of clinical expertise, it is the gap between what we know clinically and how consistently that knowledge is applied in practice.
If the Modern Service Framework is to deliver real progress for our community, several issues must be addressed.
Better Awareness in Primary Care
Primary care is the front door of the NHS. It is where most patients first present with symptoms. Yet heart valve disease does not always feature prominently in routine clinical thinking, particularly when symptoms overlap with other long-term conditions.
Improving awareness in primary care is not about adding burden; it is about sharpening focus. For patients over 60, and particularly over 70, new or worsening breathlessness, reduced exercise tolerance, unexplained fatigue, chest discomfort or lightheadedness should trigger consideration of valvular disease. A simple stethoscope examination remains a powerful diagnostic tool when used consistently - digital solutions offer exciting promise too.
We also know that inequalities exist. Women’s symptoms are often undetected. Patients in more deprived communities may experience longer delays. Cultural and language barriers can affect how symptoms are described or understood. If awareness is not strengthened across the whole system, these disparities will persist.
Embedding heart valve disease more firmly within routine primary care practice, whether through professional education, clearer prompts within NHS Health Checks, or strengthened pathways, is a practical and achievable step.
Early Diagnosis and Access to Echocardiography
Awareness alone is not enough without access to diagnostics, echocardiography is the gold standard for diagnosing valve disease, yet access to echo can vary significantly across regions, with waiting times creating bottlenecks that delay definitive diagnosis.
When echo is delayed, everything that follows is delayed: referral to specialists, multidisciplinary discussion, treatment planning. For a progressive condition such as aortic stenosis, time matters. Delayed diagnosis increases the risk of deterioration, emergency admission and poorer outcomes.
The MSF presents an opportunity to consider how diagnostic capacity aligns with population needs. As the UK population ages, demand for echo will increase and planning must reflect this reality. Modernisation should mean expanding and streamlining diagnostic access so that early suspicion in primary care leads swiftly to clarity.
In practical terms, early diagnosis must become routine rather than reactive. The goal should be that patients are identified and referred before they reach a crisis point, not because they have collapsed or been admitted through A&E.
Rapid Pathways: RAVA and Single Points of Access
Once diagnosed, patients should not face further fragmentation. In areas where Rapid Access Valve Assessment (RAVA) clinics exist (Manchester Federation Trust a perfect example), we see the benefits of coordinated, specialist-led evaluation. These pathways reduce delays, improve patient experience and support timely elective treatment.
However, access to these types of services remains inconsistent across the country. In some regions, patients move smoothly from diagnosis to specialist assessment. In others, they encounter multiple referral steps, repeated appointments and long waits.
The concept of a Single Point of Access for valve disease is equally important. Clear, streamlined referral routes reduce duplication, minimise confusion and ensure patients are seen by the right team without unnecessary delay. For clinicians, it simplifies decision-making. For patients, it reduces anxiety and uncertainty.
The MSF should provide an opportunity to examine variation and support more consistent adoption of rapid, coordinated pathways.
The Risks of Inaction
While I am optimistic about the direction of travel, I am also clear about the risks.
If heart valve disease is not fully considered within the MSF, the status quo will continue. We will see ongoing postcode variation. Patients will continue to present late, emergency admissions will remain higher than they need to be. I am afraid I predict inequalities will widen, rather than narrow.
There is also a financial risk. Late presentation is more costly to the NHS than timely elective care. Emergency admissions, prolonged hospital stays and more complex interventions place greater strain on resources. Early detection and planned treatment are not only better for patients, they are more sustainable for the system.
Most importantly, there is a human cost as behind every delayed diagnosis is a person who may have lost confidence, independence or precious time with family. Carers often shoulder the burden of navigating a confusing system while watching a loved one deteriorate.
Equity Must Be Central
One of the stated aims of the MSF is to reduce variation in care. For heart valve disease, this is critical. Treatment rates in the UK have historically lagged behind some European counterparts, and within the UK itself, geographic disparities persist.
Modern services must mean equitable services. Access to diagnostics, specialist assessment and treatment should not depend on where someone lives. Nor should gender, ethnicity or socioeconomic status influence the speed or quality of care.
A Constructive Partnership
At Heart Valve Voice, we see our role as constructive partners. We bring the lived experience of patients into policy conversations. We highlight where gaps exist. And we work with clinicians, commissioners and policymakers to identify solutions. Our involvement in the MSF data-gathering process was an important step as it demonstrated recognition that patient voice matters. As the Framework evolves, continued collaboration will be essential.
We do not seek to create unnecessary complexity. In fact, much of what we are calling for is simple:
- Stronger awareness of heart valve disease in primary care.
- Timely access to echocardiography.
- Consistent adoption of rapid assessment pathways such as RAVA.
- Clear Single Points of Access to specialist services.
- A deliberate focus on reducing inequality and variation.
These are practical measures grounded in existing evidence and clinical practice.
I recognise that cost and capacity are significant pressures for both Government and the NHS. Calling for better awareness and earlier access to diagnostics is not about overwhelming the system with incidental or mild findings that require no intervention. It is about identifying clinically significant valve disease earlier, the patients whose condition is progressive, serious and potentially life-limiting if left untreated. Heart valve disease is common, particularly in an ageing population. It is serious, but it is also highly treatable when detected in time.
Earlier diagnosis supports planned, elective care, improves outcomes and ultimately represents a more responsible use of NHS resources than late crisis intervention.
Wil Woan is the Executive Director of Heart Valve Voice, the UK’s dedicated heart valve disease charity